ecrin-mdr-crcClinical2007Metastatic Colorectal CancerColorectal NeoplasmsPatients with metastatic colorectal cancerMetastatic Colorectal CancerPatients With Metastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2042621SwedenAustriaBelgiumFranceGermany5PanitumumabECRIN MDRCompletedfalsePanitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerTo estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line therapy for metastatic colorectal cancer (mCRC).2007-05-152042621NCT005084042006-006739-36